Proactive Investors - Run By Investors For Investors

VentriPoint's VMS System used to test 500 Sarcoidosis patients in Netherlands

Ventripoint Diagnostics (CVE:VPT-OTCQB-VPTDF) CEO George Adams  joined Steve Darling from Proactive Investors Vancouver on Skype with news their VMS System was used to study patients with Sarcoidosis, an inflammatory disease that affects multiple organs in the body, including the heart.

Adams told Proactive how many patients where in the study and how the company will be using this data going forward. Adams also had an update on what the company will be doing in China in 2019.

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use